High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer

Eliahu Ge Z; Susan Goodman; Rut Isaeson; Cilla Gerra; Aaron Sulkes

doi:10.1159/000226358

High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer

Eliahu Ge Z^*, Susan Goodman, Rut Isaeson, Cilla Gerra, Aaron Sulkes

^*Corresponding author for this work

Hadassah University Medical Centre

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2×2 mg. kg and 2×0-2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: Drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.

Original language	English
Pages (from-to)	173-175
Number of pages	3
Journal	Oncology
Volume	43
Issue number	3
DOIs	https://doi.org/10.1159/000226358
State	Published - 1986
Externally published	Yes

Keywords

5-Fluorouracil
Antiemetic
CMF chemotherapy
Cyclophosphamide
Dexamethasone
Methotrexate
Metoclopramide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000226358

Cite this

@article{9c931fa626584fd98ff32f6832464224,

title = "High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer",

abstract = "Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2×2 mg. kg and 2×0-2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: Drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.",

keywords = "5-Fluorouracil, Antiemetic, CMF chemotherapy, Cyclophosphamide, Dexamethasone, Methotrexate, Metoclopramide",

author = "{Ge Z}, Eliahu and Susan Goodman and Rut Isaeson and Cilla Gerra and Aaron Sulkes",

year = "1986",

doi = "10.1159/000226358",

language = "אנגלית",

volume = "43",

pages = "173--175",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer

AU - Ge Z, Eliahu

AU - Goodman, Susan

AU - Isaeson, Rut

AU - Gerra, Cilla

AU - Sulkes, Aaron

PY - 1986

Y1 - 1986

N2 - Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2×2 mg. kg and 2×0-2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: Drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.

AB - Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2×2 mg. kg and 2×0-2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: Drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.

KW - 5-Fluorouracil

KW - Antiemetic

KW - CMF chemotherapy

KW - Cyclophosphamide

KW - Dexamethasone

KW - Methotrexate

KW - Metoclopramide

UR - http://www.scopus.com/inward/record.url?scp=0022592582&partnerID=8YFLogxK

U2 - 10.1159/000226358

DO - 10.1159/000226358

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0022592582

SN - 0030-2414

VL - 43

SP - 173

EP - 175

JO - Oncology

JF - Oncology

IS - 3

ER -

High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this